Indivior Pharmaceuticals, Inc. Current Financial Assets At Fair Value Through Profit Or Loss
Indivior Pharmaceuticals, Inc. (INDV) had Current Financial Assets At Fair Value Through Profit Or Loss of $10.00 million as of 2023-12-31, per its 20-F filed 2024-03-06.
Discontinued › Notes
ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLoss · last filed 2024-03-06
- 2023-12-31: Current Financial Assets At Fair Value Through Profit Or Loss $10.00M.
- 2022-12-31: Current Financial Assets At Fair Value Through Profit Or Loss $10.00M.
| Period end | Current Financial Assets At Fair Value Through Profit Or Loss |
|---|---|
| 2023-12-31 | $10.00M 20-F · filed 2024-03-06 |
| 2022-12-31 | $10.00M 20-F · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |